Company’s quarterly revenues reach €6.3B ($6.7B) in 3-month period that ended on March 31
The German pharma firm BioNTech on Monday said its vaccine sales were more than tripled, with a €6.3 billion ($6.7 billion) revenue in the three-month period that ended on March 31.
In the first quarter of 2021, the figure was €2.05 billion, according to the company’s financial results.
Its net profit also jumped to €3.7 billion from this January to March, up from €1.1 billion a year ago.
“As a result of an increased order volume initially placed in late 2021 following the then-emerging Omicron variant, we began the year 2022 with strong revenues and earnings, leaving us well-positioned to achieve the 2022 financial guidance we issued a few months ago,” Jens Holstein,the CFO of BioNTech, said.
The company estimated lower vaccine revenue for the full year at €13-€17 billion, down from €19 billion in 2021.